SYRS - Syros Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.81
-0.26 (-2.15%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.07
Open12.10
Bid10.15 x 100
Ask12.40 x 1000
Day's Range11.65 - 12.10
52 Week Range6.30 - 24.38
Volume109,626
Avg. Volume199,068
Market Cap384.75M
Beta-2.60
PE Ratio (TTM)N/A
EPS (TTM)-2.10
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.33
Trade prices are not sourced from all markets
  • Business Wire12 days ago

    Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018

    Syros Pharmaceuticals (SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a key opinion leader (KOL) breakfast symposium focused on the unmet need, treatment landscape and opportunity for new combination approaches in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) from 8:30-10:30 a.m. ET on Tuesday, July 17, 2018 in New York City. Syros is currently evaluating SY-1425, its first-in-class, selective retinoic acid receptor alpha (RARα) agonist, in a Phase 2 clinical trial in combination with standard-of-care and targeted therapies in genomically defined subsets of AML and MDS patients.

  • 2 Stable and 2 Speculative Biotech Stocks to Buy
    InvestorPlacelast month

    2 Stable and 2 Speculative Biotech Stocks to Buy

    Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.

  • Business Wirelast month

    Syros Announces Appointment of Michael W. Bonney to Its Board of Directors

    Syros Pharmaceuticals (SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced the appointment of Michael W. Bonney to the Company’s Board of Directors. Mr. Bonney brings extensive strategic, operational, commercial and leadership experience in the biotechnology industry. “Mike is a highly regarded and accomplished leader with a proven record of building successful commercial enterprises based on a strong strategic vision, operational excellence and a passion for bringing important therapies to market for patients,” said Nancy Simonian, M.D., Chief Executive Officer of Syros.

  • Business Wire2 months ago

    Syros to Present at Upcoming Investor Conferences

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at upcoming investor conferences.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Syros Pharmaceuticals, J & J Snack Foods, Wright Medical Group N.V, HCI Group, Tennant, and Ebix — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, May 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Syros ...

  • Business Wire2 months ago

    Syros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual Meeting

    Syros Pharmaceuticals (SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that the Company will present on the design of its Phase 1 clinical trial of SY-1365, a first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 1-5, 2018 in Chicago. The Phase 1 trial is currently enrolling advanced solid tumor patients in the dose-escalation portion of the trial, with planned expansion cohorts to further evaluate SY-1365 as a single agent and in combination with standard-of-care therapies in multiple ovarian and breast cancer patient populations.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SYRS earnings conference call or presentation 10-May-18 12:30pm GMT

    Q1 2018 Syros Pharmaceuticals Inc Earnings Call

  • Business Wire2 months ago

    Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today reported financial results for the quarter ended March 31, 2018 and provided an update on recent accomplishments and upcoming events.

  • Business Wire3 months ago

    Syros to Report First Quarter 2018 Financial Results on Thursday, May 10, 2018

    Syros Pharmaceuticals (SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 10, 2018 to report its first quarter 2018 financial results and provide a corporate update. Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control the expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.

  • Business Wire3 months ago

    Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced new preclinical data showing that SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 trial in patients with advanced solid tumors, demonstrated potent anti-tumor activity in multiple models of heavily ...

  • Incyte Advances R&D Strategy with Multiple Partnerships
    Market Realist3 months ago

    Incyte Advances R&D Strategy with Multiple Partnerships

    In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.

  • Incyte’s Collaborations and Developments in 2018
    Market Realist4 months ago

    Incyte’s Collaborations and Developments in 2018

    Incyte (INCY) has a well-established distribution network in the US and sells Jakafi and Iclusig in the country through its own network. For sales outside the US market, the company entered into an agreement with Novartis (NVS) to develop and commercialize Jakafi. Novartis sells Jakafi under the name of Jakavi, and Incyte receives royalties on the total sales of Jakavi. The chart below compares the royalty revenues and contract revenues for Incyte since 1Q16.

  • Business Wire4 months ago

    Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that the Company and its collaborators from the Dana-Farber Cancer Institute will present new preclinical data on SY-1365, a first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 trial in patients with advanced solid ...

  • Business Wire4 months ago

    Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today reported financial results for the fourth quarter and year ended December 31, 2017 and provided an update on recent accomplishments and planned upcoming events.

  • Business Wire4 months ago

    Syros Announces Appointment of Joseph J. Ferra as Chief Financial Officer

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced the appointment of Joseph J.

  • Business Wire5 months ago

    Syros to Present at Upcoming Investor Conferences

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at upcoming investor conferences.

  • Business Wire5 months ago

    Syros to Present at Leerink Partners 7th Annual Global Healthcare Conference

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Leerink Partners 7th Annual Global Healthcare Conference.

  • Business Wire5 months ago

    Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 628,272 shares at the public offering price of $9.55 per share.

  • Business Wire6 months ago

    Syros Announces Pricing of $40 Million Public Offering of Common Stock

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced that it has priced an underwritten public offering of 4,188,481 shares of common stock at a price to the public of $9.55 per share, before underwriting discounts and commissions, which would result in aggregate gross proceeds of approximately $40.0 million....

  • Business Wire6 months ago

    Syros Announces Proposed Offering of Common Stock

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced that it is offering to sell, subject to market and other conditions, $40.0 million of its common stock in an underwritten public offering.

  • Business Wire6 months ago

    Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARα Agonist

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced that the U.S. Patent and Trademark Office has issued two patents covering methods for stratifying patients with acute myeloid leukemia and myelodysplastic syndrome for treatment with SY-1425 , the Company’s first-in-class selective retinoic acid receptor alpha ...

  • Business Wire6 months ago

    Syros Announces 2018 Strategic Priorities and Expected Milestones

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today outlined its strategic plan and expected milestones for 2018.

  • Business Wire6 months ago

    Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms

    Incyte Corporation and Syros Pharmaceuticals, Inc. announced today that the companies have entered into a target discovery, research collaboration and option agreement.